Literature DB >> 6305479

Necrosis as a prognostic criterion in malignant supratentorial, astrocytic gliomas.

J S Nelson, Y Tsukada, D Schoenfeld, K Fulling, J Lamarche, N Peress.   

Abstract

Surgical specimens of malignant, supratentorial, astrocytic gliomas from 503 patients randomized on an RTOG-ECOG treatment protocol were examined by central pathologic review. The diagnosis of glioblastoma multiforme (GBM) was made only when one or more foci of coagulation necrosis involving astrocytic tumor cells were identified histologically. Malignant astrocytic neoplasms without necrosis were classified as astrocytoma with atypical or anaplastic features (AAF). The median survival stratifying for treatment for patients with GBM was eight months compared to 28 months for patients with AAF. In most cases the specimens were received with a Kernohan grade. On the basis of these grades, patients with astrocytoma Grade 3 had a median survival of ten months as compared to a median survival of nine months for those with astrocytoma Grade 4. Observations demonstrate that necrosis is a reliable, decisive prognostic factor associated with malignant, supratentorial, astrocytic gliomas. The Kernohan system is of limited value in assessing prognosis for this group of tumors.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6305479     DOI: 10.1002/1097-0142(19830801)52:3<550::aid-cncr2820520327>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  48 in total

1.  A comparative survival evaluation and assessment of interclassification concordance in adult supratentorial astrocytic tumors.

Authors:  A K Karak; R Singh; P N Tandon; C Sarkar
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

2.  Pre-radiation chemotherapy in glioma patients with poor prognostic factors.

Authors:  K Watne; O Nome; B Hager; H Hirschberg
Journal:  J Neurooncol       Date:  1992-07       Impact factor: 4.130

3.  Relationship between thallium-201 uptake by supratentorial glioblastomas and their morphological characteristics on magnetic resonance imaging.

Authors:  M Ricci; P Pantano; A Pierallini; D Di Stefano; A Santoro; L Bozzao; G L Lenzi
Journal:  Eur J Nucl Med       Date:  1996-05

4.  Prognostic significance of preoperative MRI scans in glioblastoma multiforme.

Authors:  M A Hammoud; R Sawaya; W Shi; P F Thall; N E Leeds
Journal:  J Neurooncol       Date:  1996-01       Impact factor: 4.130

5.  The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial. A report from the Childrens Cancer Study Group.

Authors:  R Sposto; I J Ertel; R D Jenkin; C P Boesel; J L Venes; J A Ortega; A E Evans; W Wara; D Hammond
Journal:  J Neurooncol       Date:  1989-07       Impact factor: 4.130

6.  Dual lineage of astrocytomas.

Authors:  M Bishop; S M de la Monte
Journal:  Am J Pathol       Date:  1989-09       Impact factor: 4.307

7.  The prognostic implications of histologic classification and bromodeoxyuridine labeling index of mixed gliomas.

Authors:  M R Wacker; T Hoshino; D K Ahn; R L Davis; M D Prados
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 8.  The basis for current treatment recommendations for malignant gliomas.

Authors:  H A Fine
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

9.  Supratentorial glioblastoma: neuroradiological findings and survival after surgery and radiotherapy.

Authors:  A Pierallini; M Bonamini; M F Osti; P Pantano; F Palmeggiani; A Santoro; R Maurizi Enrici; L Bozzao
Journal:  Neuroradiology       Date:  1996-05       Impact factor: 2.804

Review 10.  Fast neutron therapy for malignant astrocytomas. A review.

Authors:  P D Kurup; T F Pajak; J S Nelson; J Mansell; F R Hendrickson; L Cohen; T W Griffin
Journal:  J Neurooncol       Date:  1986       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.